Visit the Canopy Growth Corp Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.
OTTAWA, July 6, 2017 /CNW/ – The Canadian AIDS Society announced today a first of its kind research program funded by Canopy Growth Corporation (TSX: WEED) (OTC: TWMJF). The program is designed to provide up-to-date information on the current state of evidence and research pertaining to the use of cannabis for medical purposes and to build tools for healthcare professionals to allow them to confidently assess and prescribe cannabis to appropriate patients.
Funded over two years at $100,000 per year by Canopy Growth Corporation — and guided by a newly created Cannabis Research Task Force of experts in the field of cannabinoid medicine — the project aims to develop guidelines and recommendations regarding the medical use of cannabis for optimal wellness, quality of life and pain management.
“Our goal is to leverage our existing knowledge and expertise in both HIV and the use of cannabis for medical purposes to create a better quality of life for many Canadians facing debilitating health conditions — particularly in the area of chronic pain management,” said Gary Lacasse, Executive Director of the Canadian AIDS Society. “This project builds on a body of existing knowledge and research developed by CAS over several years.”
The Task Force will be addressing issues surrounding the current lack of information — for Canadian health care practitioners and ultimately for patients — regarding guidance on the use of cannabis for medical or therapeutic purposes. It is estimated that 10% of Canadian physicians have written an authorization for medical cannabis.
“We are confident that this partnership with the Canadian AIDS Society and the broad medical and social expertise of the Task Force will result in practical guidelines for the use of cannabis that can be applied to many medical conditions,” said Mark Zekulin, President, Canopy Growth Corporation. “We have dedicated a great deal of effort toward physician education over the last three years and I feel confident that this work will create another valuable tool that Canadian healthcare professionals and Canadians alike can use when considering cannabis as a therapy..”
The Cannabis Research Task Force is expected to review the current state of research for the use of medical cannabis and develop a scope of work for evidence-based Canadian guidelines in such areas as treatment, contraindications, dosing, chronic pain, risk management and regulatory issues, among others.
Cannabis Research Program
Funded by Canopy Growth Corporation
- In Canada, approximately 75,500 are living with HIV and about 250,000 are living with hepatitis C (HCV)
- Cannabis has been proven to be effective to relieve symptoms — including chronic pain management — related to many medical conditions.
- The Cannabis Research Task Force brought together by the Canadian AIDS Society is expected to review the current state of research for the use of medical cannabis and develop a scope of work for evidence-based Canadian guidelines in such areas as treatment, contraindications, dosing, chronic pain, risk management and regulatory issues, among others.
As of July 6, 2017, the members of the Cannabis Research Task Force include:
About the Canadian AIDS Society (CAS)
The Canadian AIDS Society (CAS) is a national coalition of community-based AIDS organizations across Canada. CAS is dedicated to strengthening the response to HIV/AIDS across all sectors of society, and to enriching the lives of people and communities living with, or affected by, HIV/AIDS. For more information, please visit www.cdnaids.ca.
About Canopy Growth Corporation (CGC)
Canopy Growth is a world-leading diversified cannabis company, offering distinct brands and curated cannabis varieties in dried, oil and capsule forms. Through its wholly owned subsidiaries, Canopy Growth operates numerous state-of-the-art production facilities with over half a million square feet of GMP-certified indoor and greenhouse production capacity, all to an unparalleled level of quality assurance procedures and testing. Canopy Growth has established partnerships with leading sector names in Canada and abroad, with interests and operations spanning four continents. The Company is proudly dedicated to educating healthcare practitioners, providing consistent access to high-quality cannabis products, conducting robust clinical research, and furthering the public’s understanding of cannabis. For more information visit www.canopygrowth.com.
For fact-based information on Canopy Growth Corp, view the company’s sponsored Investor Dashboard.
Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.